Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Paclitaxel Trevatide |
Synonyms | |
Therapy Description |
Paclitaxel Trevatide (GRN1005) consists of paclitaxel bound to a peptide that binds LRP-1, which allows the drug-peptide conjugate to cross the blood-brain barrier and delivers paclitaxel to LRP-1 expressing tumor cells (PMID: 22203732, PMID: 23349317). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel Trevatide | ANG1005|GRN1005 | Chemotherapy - Taxane 3 | Paclitaxel Trevatide (GRN1005) consists of paclitaxel bound to a peptide that binds LRP-1, which allows the drug-peptide conjugate to cross the blood-brain barrier and delivers paclitaxel to LRP-1 expressing tumor cells (PMID: 22203732, PMID: 23349317). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02048059 | Phase II | Paclitaxel Trevatide | ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases | Completed | USA | 0 |
NCT01967810 | Phase II | Bevacizumab Paclitaxel Trevatide | ANG1005 in Patients With Recurrent High-Grade Glioma | Completed | USA | 0 |